Breast-cancer screening benefits are limited; false alarms loom

By H. GILBERT WELCH

Los Angeles Times

If you haven’t gotten this message already, you should heed it now: The benefits of screening for breast cancer are limited. We should be doing fewer screening mammograms, not more.

The data that support this conclusion come from studying the effects of mammography across time and place.

A couple of years ago, a colleague and I reported on the effect across time. We found that the initiation of widespread screening in the U.S. during the 1980s was associated with a substantial increase in the number of women found with early-stage breast cancer, but it didn’t yield much of a decrease in the number found with serious late-stage cancer. And no change in the worst stage: The number diagnosed with life-threatening metastatic breast cancer didn’t decrease.

That so few women who ended up with serious breast cancer had their time of diagnosis advanced (to early-stage) suggests that the benefit of screening is very limited. And yet having so many additional women diagnosed with early-stage cancer suggests screening leads to a lot of overdiagnosis, unnecessary treatment and anxiety.

Natural experiment

As to the effect across place, in an article published this month in JAMA Internal Medicine, Harvard colleagues and I reported on breast cancer in 547 counties in the U.S. The study was a natural experiment: It made use of the fact that screening-mammography rates vary considerably by county.

We found that counties that screened more found significantly more breast cancer. But there was no relationship between how much a county screened for breast cancer and how likely its female residents were to die from breast cancer. In other words, once again the benefit of screening was very limited and once again it led to diagnoses of cancers that otherwise would have never bothered women.

This conclusion was further supported by data on cancer size. More screening was strongly associated with more detection of small breast cancers. But more screening was not associated with less detection of serious late-stage cancers.

Over time and over place, the findings are consistent: Screening is good at finding small breast cancers. Unfortunately, the small cancers it finds seem to be those not destined to become large, deadly cancers.

Important disease

Let me be clear about what I am not saying. I am not saying breast cancer is not an important disease. It is arguably the most important cancer for a nonsmoking woman to worry about. I am not saying there is no good news about breast cancer. Quite the opposite: The huge strides in breast- cancer treatment represent unambiguously good news. Nor am I saying you shouldn’t get a mammogram if you notice a new breast lump. Doctors agree that mammography is a good diagnostic test; the debate is about screening mammography. And I’m not saying that screening never helps anyone. It may, but it without doubt has harms.

Given the evidence of its limited benefit, we really need to limit the harms of screening.

The most frequent harm is the false alarm. To be sure, the effect of a false alarm on a woman is highly variable, ranging from a minor inconvenience (simply requiring a repeat exam) to a seemingly endless cycle of repetitive testing that, although it never detects cancer, also never comes back “normal.” According to data from the Breast Cancer Surveillance Consortium, more than half of women will have at least one false alarm during a 10-year course of annual screenings.

But a 50 percent rate of false alarms is neither humane nor efficient. The public health community should be outraged. Our European colleagues wince at our performance; their false-alarm rates are less than half ours.

But the bigger harm is actually overdiagnosis. Women are being diagnosed with breast cancer, and receiving some combination of surgery, chemotherapy and/or radiation, when, in fact, that cancer was not destined to cause symptoms – a lump you can feel – or be life-threatening. Screening mammography is more likely to cause overdiagnosis than it is to help save lives.

LOOKING HARDER

Yet there is an entire industry devoted to looking harder still. Three-dimensional mammography is promoted as finding 40 percent more breast cancer than conventional screening. The addition of ultrasound finds 50 percent more breast cancer than conventional screening. Adding an MRI doubles the amount of breast cancer found. And this year Mayo Clinic researchers reported finding almost four times more breast cancer using molecular breast imaging.

Looking harder isn’t the right way to combat breast cancer. What do we get when we look harder? More false alarms and more overdiagnosis – with no obvious change in what we care about: breast-cancer deaths.

Why are we doing it? Having so much money on the table doesn’t help. American women and insurers are estimated to spend $8 billion annually on breast cancer screening, and that’s before the adoption of 3-D mammography. Lawyers don’t help either; doctors who might counsel fewer mammograms or be less aggressive in pursuing breast abnormalities are afraid of lawsuits in the few instances in which serious cancer later develops.

But the biggest problem seems to be a lack of leadership in the mammography community. While their colleagues in other areas of radiology are working to mitigate false alarms and overdiagnosis in lung cancer screening and in the evaluation of thyroid nodules and small kidney masses, a small, vocal group of mammographers seems content to dismiss the problems with breast cancer screening.

They shouldn’t be able to drown out the facts: More mammograms do not promote women’s health.

H. Gilbert Welch is a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice and the author of “Less Medicine, More Health: 7 Assumptions that Drive Too Much Medical Care.” He wrote this for the Los Angeles Times.